90 filings
Page 4 of 5
6-K
mfyp vdwzgoy
29 Jul 21
Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
6:05am
6-K
gm9pqae6o25zt
1 Jul 21
Current report (foreign)
6:05am
6-K
vc5izlum8i5
30 Jun 21
Current report (foreign)
12:00am
6-K
0djrpfe75r0v
29 Jun 21
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
6:05am
6-K
rdfv 04pitdvtme7j
17 Jun 21
Addex Shareholders Approve All Resolutions at Annual General Meeting
6:05am
6-K
n1lwiawe06gyxebk
7 Jun 21
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
6:05am
6-K
auju8m5 4eijus9
17 May 21
Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
12:00am
6-K
ltxekluejs8j0
14 May 21
Addex Convenes Annual General Meeting 2021
6:05am
6-K
kyfvv7l feicl
5 May 21
Current report (foreign)
6:02am
6-K
bnlcz8pa k4kscrx
26 Apr 21
Addex Increases Issued Share Capital to Create Treasury Shares
6:05am
6-K
fohyg k5tqtblij
8 Apr 21
Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
6:05am
6-K
fhvbo6do 0tn55m57ajb
11 Mar 21
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
6:10am
6-K
mhubmww mj
17 Feb 21
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
6:05am
6-K
4b4w7q6e
16 Feb 21
Current report (foreign)
6:05am
6-K
bafgybne uu8yc71
21 Jan 21
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
6:05am
6-K
2qa4wueqb 20
12 Jan 21
Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
7:36am
6-K
qao2 jbtveh0y
7 Jan 21
Addex Announces Pricing of $10.0 Million Global Offering
12:00am
6-K
v4ayyv4bgj0fvuwx 36
14 Dec 20
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
12:37pm
6-K
6sk0 iwj30c
3 Nov 20
Current report (foreign)
6:01am
6-K
qutu 7a6oc9v
2 Nov 20
Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
6:05am